Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-02

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To learn if a process called neuromodulation can help to improve pain due to CIP

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy

NCT06389721

Chemotherapy-induced Peripheral Neuropathy

RECRUITING

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

NCT06744816

Peripheral Neuropathy Due to Chemotherapy

RECRUITING EARLY_PHASE1

MC-5A for Chemotherapy Induced Peripheral Neuropathy

NCT01261780

Neuropathy, Paraneoplastic

COMPLETED PHASE2

The Role of TRP Channels in CIPN

NCT04415892

Chemotherapy-induced Peripheral Neuropathy

RECRUITING NA

Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer

NCT00281853

Neurotoxicity Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document
* Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
* Patients seen at Pain Management Center at MD Anderson Cancer Center
* Patient ages greater or equal to 18 years but less than or equal to 85 years

Exclusion Criteria:

* Patients with cognitive dysfunction
* Patient with recent history (\<6 months) of drug or alcohol abuse
* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
* Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathy;Peripheral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Group 1 will receive neuromodulation.

Group Type EXPERIMENTAL

Abbott® DRG / Abbott®/Medtronic® SCS

Intervention Type DEVICE

Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.

Control Group

Group 2 will not receive neuromodulation.

Group Type EXPERIMENTAL

Control Group

Intervention Type OTHER

Participants will not receive any intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abbott® DRG / Abbott®/Medtronic® SCS

Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.

Intervention Type DEVICE

Control Group

Participants will not receive any intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand and the willingness to sign a written informed consent document
* Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
* Patients seen at Pain Management Center at MD Anderson Cancer Center
* Patient ages greater or equal to 18 years but less than or equal to 85 years

Exclusion Criteria

* Patients with cognitive dysfunction
* Patient with recent history (\<6 months) of drug or alcohol abuse
* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
* Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No